Article
Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif.
Antimicrobial agents and chemotherapy - 1 Nov 2006
Yatsuji Hiromi, Noguchi Chiemi, Hiraga Nobuhiko, Mori Nami, Tsuge Masataka, Imamura Michio, Takahashi Shoichi, Iwao Eiji, Fujimoto Yoshifumi, Ochi Hidenori, Abe Hiromi, Maekawa Toshiro, Tateno Chise, Yoshizato Katsutoshi, Suzuki Fumitaka, Kumada Hiromitsu, Chayama Kazuaki
Abstract excerpt
Lamivudine is a major drug approved for treatment of chronic hepatitis B virus (HBV) infection. Emergence of drug-resistant mutants with amino acid substitutions in the YMDD motif is a well-documented problem during long-term lamivudine therapy. Here we report a novel lamivudine-resistant strain of HBV with an intact YMDD motif, which included an amino acid substitution, rtA181T, in the reverse transcriptase (RT)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.